Market Place
Sourcing Support
Biosion Announces Global License with Aclaris for Immunology Assets
18 Nov 2024 //
PR NEWSWIRE
Aclaris Therapeutics Reports Q3 2024 Financial Results & Update
06 Nov 2024 //
GLOBENEWSWIRE
Aclaris Therapeutics Doses First Patient in ATI-2138 Phase 2a Trial
17 Sep 2024 //
GLOBENEWSWIRE
Aclaris To Join 2024 Cantor Global Healthcare Conference
10 Sep 2024 //
GLOBENEWSWIRE
Aclaris Therapeutics Reports Q2 2024 Results And Corporate Update
07 Aug 2024 //
GLOBENEWSWIRE
Aclaris Sells OLUMIANT Royalties To OMERS Life Sciences For Up To $31.5M
16 Jul 2024 //
GLOBENEWSWIRE
Aclaris To Participate In Goldman Healthcare Conference
06 Jun 2024 //
GLOBENEWSWIRE
Aclaris Therapeutics Q1 2024 Results and Update
06 May 2024 //
GLOBENEWSWIRE
Aclaris Q1 2024 Results on May 7, Corporate Update
30 Apr 2024 //
GLOBENEWSWIRE
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 2024 //
GLOBENEWSWIRE
Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review
16 Jan 2024 //
GLOBENEWSWIRE
Aclaris Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777
10 Jan 2024 //
GLOBENEWSWIRE
Aclaris lays off 46%, resurrects zunsemetinib for cancer
20 Dec 2023 //
FIERCE BIOTECH
Aclaris halves headcount, banks on next mid-stage readout after setbacks
19 Dec 2023 //
ENDPTS
Aclaris Therapeutics Provides Corporate Update
19 Dec 2023 //
GLOBENEWSWIRE
Aclaris Announces Patent License Agreement with Sun Pharma for Alopecia
05 Dec 2023 //
GLOBENEWSWIRE
Aclaris Announces Results from 12-Week Phase 2b Trial of Oral Zunsemetinib
13 Nov 2023 //
GLOBENEWSWIRE
Aclaris shares plummet on terminating development of rheumatoid arthritis drug
13 Nov 2023 //
REUTERS
Aclaris Therapeutics Reports Third Quarter 2023 Financial Results
06 Nov 2023 //
GLOBENEWSWIRE
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777
03 Oct 2023 //
GLOBENEWSWIRE
Aclaris to Participate in the 2023 Cantor Global Healthcare Conference
20 Sep 2023 //
GLOBENEWSWIRE
Aclaris Announces Positive Results from Phase 1 Trial of ATI-2138
18 Sep 2023 //
GLOBENEWSWIRE
Aclaris Therapeutics Reports Second Quarter 2023 Financial Results
07 Aug 2023 //
GLOBENEWSWIRE
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib
13 Jun 2023 //
GLOBENEWSWIRE
Aclaris Therapeutics to Participate in Two June Healthcare Investor Conferences
02 Jun 2023 //
GLOBENEWSWIRE
Aclaris Therapeutics Reports 1Q 2023 FYR and Provides a Corporate Update
08 May 2023 //
GLOBENEWSWIRE
Aclaris Therapeutics to Announce First Quarter 2023 FYR on May 8, 2023
02 May 2023 //
GLOBENEWSWIRE
Aclaris to Participate in H.C. Wainwright Autoimmune Disease Conference
27 Mar 2023 //
GLOBENEWSWIRE
Aclaris shares tank as skin disorder drug fails mid-stage study
07 Mar 2023 //
REUTERS
Aclaris Announces Data from 12-Week Phase 2a Study of Zunsemetinib
06 Mar 2023 //
GLOBENEWSWIRE
Aclaris Reports Fourth Quarter and Full Year 2022 Financial Results
23 Feb 2023 //
GLOBENEWSWIRE
Aclaris to Participate in the Virtual SVB Securities Global Biopharma Conference
09 Feb 2023 //
GLOBENEWSWIRE
Dr. Vince Clinical Research Announce Dosing of Aclaris’ PI MAD Study of ATI-2138
11 Jan 2023 //
BUSINESSWIRE
Aclaris Therapeutics Provides 2023 Outlook
06 Jan 2023 //
GLOBENEWSWIRE
Aclaris and Pediatrix Announce License Agreement for ATI-1777 in Greater China
29 Nov 2022 //
GLOBENEWSWIRE
Aclaris Therapeutics Announces Key Leadership Transitions
22 Nov 2022 //
GLOBENEWSWIRE
Aclaris Therapeutics to Participate in Two November Healthcare Investor
10 Nov 2022 //
GLOBENEWSWIRE
Aclaris Reports3Q 2022 Financial Results and Provides a Corporate Update
08 Nov 2022 //
GLOBENEWSWIRE
Aclaris Therapeutics Appoints Robert Doody as VP, Investor Relations
27 Sep 2022 //
GLOBENEWSWIRE
Aclaris Therapeutics Appoints Robert Doody as Vice President, Investor Relations
27 Sep 2022 //
GLOBENEWSWIRE
Aclaris Therapeutics to Participate in the H.C. Wainwright 24th Annual
30 Aug 2022 //
GLOBENEWSWIRE
Aclaris Announces Patent License Agreement with Lilly for Alopecia Areata
25 Aug 2022 //
GLOBENEWSWIRE
Aclaris Therapeutics Reports Second Quarter 2022 Financial Results
03 Aug 2022 //
GLOBENEWSWIRE
Aclaris Therapeutics Expands Leadership Team
01 Aug 2022 //
GLOBENEWSWIRE
Aclaris Therapeutics Expands Leadership Team
27 Jun 2022 //
GLOBENEWSWIRE
Aclaris Therapeutics to Participate in the Jefferies Healthcare Conference
01 Jun 2022 //
GLOBENEWSWIRE
Aclaris Therapeutics to Participate in the H.C. Wainwright Conference
16 May 2022 //
GLOBENEWSWIRE
Aclaris Therapeutics Reports First Quarter 2022 Financial Results
10 May 2022 //
GLOBENEWSWIRE
Aclaris to Participate in LifeSci Partners Immunology & Inflammation Symposium
03 May 2022 //
GLOBENEWSWIRE
Aclaris Tx Reports Q4 and Full Year 2021 Financial Results
24 Feb 2022 //
GLOBENEWSWIRE
Aclaris Therapeutics Expands Leadership Team
01 Feb 2022 //
GLOBENEWSWIRE
Aclaris Therapeutics Provides R&D Update
11 Jan 2022 //
PRESS RELEASE
Aclaris Announces Publication of Preclinical Research of Zunsemetinib
03 Dec 2021 //
GLOBENEWSWIRE
Aclaris` RA candidate bolsters chemo in pancreatic cancer models
01 Dec 2021 //
FIERCEBIOTECH
Aclaris Announces Settlement Hearing of Stockholder Derivative Action
27 Aug 2021 //
GLOBENEWSWIRE
Aclaris Therapeutics to Participate in the William Blair Conference 2021
08 Jul 2021 //
GLOBENEWSWIRE
Aclaris Announces Positive Preliminary Data from Phase 2a Trial of ATI-1777
08 Jun 2021 //
GLOBENEWSWIRE
Aclaris Completes Enrollment in its Phase 2a Clinical Trial of ATI-1777
15 Mar 2021 //
GLOBENEWSWIRE
Aclaris Announces Positive Topline from 12-Week Ph 2a of Oral ATI-450
19 Jan 2021 //
PRESS RELEASE
Aclaris Therapeutics Announces Formation of New Scientific Advisory Board
15 Dec 2020 //
GLOBENEWSWIRE
